Evgen Limited

Development of a novel anti-cancer agent, Sulforadex. Now in Phase I, it is initially being developed for prostate and breast cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Liverpool, England, GB
  • Currency GBP
  • Founded January 2008
  • Employees 4
  • Website evgen.com

Company Summary

Evgen Limited is developing a novel cancer therapeutic called Sulforadex®, initially for early stage prostate cancer and prevention of recurrence of breast cancer. The product is in Phase I clinical trials. Sulforadex is a patented composition comprising a stabilised form of sulforaphane, a molecule that is well recognised for its therapeutic potential in a broad range of cancers but has hitherto been non-viable as a pharmaceutical.

Team

  • Barry Clare
    Chairman

    Twenty years experience in the healthcare industry. Former main board director of Boots Company plc. More recently has established several private equity transactions that have successfully exited.

  • Alan Barge
    Chief Medical Advisor

    Currently Chief Medical Officer of Singapore based ASLAN Pharmaceuticals PTE. Was VP and head of Oncology & Infection at AstraZeneca. Prior to AZ, Alan was global Medical Director for Amgen Inc.

  • Barry Furr
    Chief Scientific Advisor

    Former Chief Scientist of AstraZeneca. A reproductive biologist and endocrinologist. Barry worked on Tamoxifen. Both Zoladex & Casodex for prostate cancer were discovered in his laboratory. Barry was awarded an OBE in 2000 for his contribution to cancer research and holds a number of prestigious positions.

  • Stephen Franklin
    Chief Executive

    Over 15 years commercial experience in the life sciences industries. Founder and former CEO of Provexis plc. Previously part of ANGLE plc and held a business development role with Manchester University Biotech incubator.

  • David Howat
    Chief Development officer

    Over 18 years relevant experience in pharmaceutical industry R&D. Head of project management for KS Biomedix Holdings, a biopharmaceutical company developing a pipeline of drugs for a range of cancer indications. Director of preclinical development for NicOx SA.

  • Sue Foden
    NED

    Founder member of Cancer Research UK and former CEO of Cancer Research Campaign Technology Limited and Cancer Research Ventures Limited. Maintains a portfolio of NED & Advisory board positions.

  • Stephen Franklin

Advisors

  • Turner Parkinson LLP, Manchester
    Lawyer
    Unconfirmed
    Grunberg and Co, London
    Accountant
    Unconfirmed

Previous Investors

  • EV Group (Rising Stars Growth Fund II)
    Unconfirmed
    SPARK Impact (North West Fund for Biomedical)
    Unconfirmed
    Sarum Oncology Fund, Imprimatur Capital and high net worth syndicate
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free